Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Twitter
  • Facebook
  • LinkedIn

Understanding PD-L1


Read More Stories
May 16, 2016

Cancer immunotherapy is one of the most exciting areas of research, and has the potential to redefine the clinical care landscape for people with many types of cancer. This is because it is designed to help your own immune system recognize and fight cancer cells. There are many ways to interact the immune response, and in this story we’ll be describing one potentially important player: the PD-L1 protein.

A Tale of Two Receptors

First, some background. Our immune system has T cells that help fight off diseases. T cells are like soldiers that help the body fight infections and other diseases, including cancer.

However, cancer cells can escape this attack by expressing a protein called PD-L1. PD-L1 works like a “stop sign” to inactivate T cells.1

PD-L1 works by attaching to receptors on T cells called PD-1 and B7.1. Both PD-1 and B7.1 can inactivate T cells.2

One approach to fighting cancer is blocking the PD-L1 protein, which may prevent cancer cells from inactivating T cells through both PD-1 and B7.1.1

Targeting PD-L1

The PD-L1 protein is an important target in cancer research. Blocking PD-L1 can prevent cancer cells from inactivating T cells through both PD-1 and B7.1. However, healthy cells may also be affected by an increased immune response.3

  •   References Down arrow

    1 Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580-6587.

    2 Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligand in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.

    3 Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.


Tags:

  • Follow the Science,
  • Cancer Immunotherapy

Read More Stories

Read about breakthrough science, the everyday people who make it happen, and the patients we serve.

  • Now Hiring
  • Find A Job
  • Professional Areas
  • Diversity & Inclusion
  • Chief Diversity Officer
  • Fostering Belonging
  • Health Equity
  • Advancing Inclusive Research
  • Transforming Society
  • Our 2021 Diversity & Inclusion Report
  • Our Work in Action
  • Kindergarten to Careers
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Financial Support
  • Genentech Patient Foundation
  • Understanding Insurance
  • Medicine Information Support
  • Clinical Trial Information
  • Advancing Inclusive Research
  • Our Approach to Pricing
  • Patient Advocacy
  • Create With Us
  • Disease Education
  • For Medical Professionals
  • Our Medicines & Products
  • Our Pipeline
  • Medical Resources
  • Clinical Trial Information
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • What We Are Looking For
  • Partner With Us
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Giving
  • Diversity & Inclusion
  • Sustainability
  • About Us
  • Leadership
  • Policy & Advocacy
  • Our Focus on Oncology
  • Awards & Recognition
  • Investors
  • Suppliers
  • Our Approach to Pricing
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
  • —
  • Privacy Policy
  • Terms & Conditions
  • Accessibility
© 2023 Genentech, Inc. All rights reserved. This site is intended for US residents only.